54.
Laliotis GP, BizelisI, Rogdakis R. “Comparative Approach of the de novo Fatty Acid
Synthesis (Lipogenesis) between Ruminant and Non Ruminant Mammalian Species: From
Biochemical Level to the Main Regulatory Lipogenic Genes.” Current Genomics. Vol. 11,
no. 3. (May 2010): 168–183. doi: 10.2174/138920210791110960.
55.
Fang EF, Lautrup S, Hou Y, Demarest TG, Croteau DL, Mattson MP, Bohr VA. “NAD(+) in
Aging: Molecular Mechanisms and Translational Implications.” Trends in Molecular
Medicine. Vol. 23, no. 10. (October 2017): 899–916. doi: 10.1016/j.molmed.2017.08.001.
56.
Katsyuba E, Auwerx J. “Modulating NAD(+) Metabolism, from Bench to Bedside.” EMBO
Journal. Vol. 36, no. 18. (September 15, 2017): 2670–2683. doi: 10.15252
/embj.201797135.
57.
Rajman L, Chwalek K, Sinclair DA. “Therapeutic Potential of NAD-Boosting Molecules: The
in vivo Evidence.” Cellular Metabolism. Vol. 27, no. 3. (March 6, 2018): 529–547.
58.
Yoshino J, Baur JA, Ima SI. “NAD(+) Intermediates: The Biology and Therapeutic Potential
of NMN and NR.” Cellular Metabolism. Vol. 27, no. 3. (March 6, 2018): 513–528.
59.
Grant RS, Kapoor V. “Murine Glial Cells Regenerate NAD, After Peroxide-Induced
Depletion, Using Either Nicotinic Acid, Nicotinamide, or Quinolinic Acid as Substrates.”
Journal oƒ Neurochemistry. Vol. 70, no. 4. (April 1998): 1759–1763.
60.
Elvehjem CA, Madden RJ, Strong FM, Woolley DW. “The Isolation and Identification of the Anti-
Black Tongue Factor.” Nutrition Reviews. Vol. 32, no. 2. (February 1974): 48–50.
61.
Mannar V, Hurrell R., editors. Food Fortiƒication in a Globalized World. London: Academic
Press/Elsevier, 2017.
62.
Kirkland JB. “Niacin Status and Treatment-Related Leukemogenesis.” Molecular Cancer
Therapeutics. Vol. 8, no. 4. (April 2009): 725–732.
63.
Kirkland JB. “Niacin Status Impacts Chromatin Structure.” Journal oƒ Nutrition. Vol. 139, no.
12. (December 2009): 2397–2401.
64.
Kirkland JB. “Niacin Status and Genomic Instability in Bone Marrow Cells; Mechanisms
Favoring the Progression of Leukemogenesis.” Subcellular Biochemistry. Vol. 56. (2012): 21–
3.
65.
Kirkland JB. “Niacin Requirements for Genomic Stability.” Mutation Research. Vol. 733, no. 1–
2. (May 1, 2012): 14–20.
66.
Menon RM, Gonzalez MA, Adams MH, Tolbert DS, Leu JH, Cefali EA. “Effect of the Rate of
Niacin Administration on the Plasma and Urine Pharmacokinetics of Niacin and Its
Metabolites.” Journal oƒ Clinical Pharmacology. Vol. 47, no. 6. (June 2007): 681–68.
67.
Peled T. “Nicotinamide, a SIRT1 Inhibitor, Inhibits Differentiation and Facilitates Expansion
of Hematopoietic Progenitor Cells with Enhanced Bone Marrow Homing and Engraftment.”
Experimental Hematology. Vol. 40, no. 4. (April 2012): 342–55.
68.
Gaikwad A, Long DJ 2nd, Stringer JL, Jaiswal AK. “In Vivo Role of NAD(P) H:Quinone
Oxidoreductase 1 (NQO1) in the Regulation of Intracellular Redox State and Accumulation
of Abdominal Adipose Tissue.” Journal oƒ Biological Chemistry. Vol. 276, no. 25. (June 22,
2001); 22559–64.
69.
Yaku K, Okabe K, Nakagawa T. “NAD Metabolism: Implications in Aging and Longevity.”
Ageing Research Reviews. Vol. 47. (November 2018): 11–7. doi: 10.1016/j.arr.2018.05.006.
